Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels
about
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradationMechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pHThe PCSK9 decadeHypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainStructure of a C-terminal AHNAK peptide in a 1:2:2 complex with S100A10 and an acetylated N-terminal peptide of annexin A2Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein ReceptorNOX1 supports the metabolic remodeling of HepG2 cellsA proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Identifying low density lipoprotein cholesterol associated variants in the Annexin A2 (ANXA2) gene.What lies ahead for the proprotein convertases?Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cellsMolecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.A new method for measurement of total plasma PCSK9: clinical applications.Annexin A2 mediates apical trafficking of renal Na⁺-K⁺-2Cl⁻ cotransporter.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.PCSK9 targets important for lipid metabolismStrategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.PCSK9: an emerging target for treatment of hypercholesterolemia.Annexins as organizers of cholesterol- and sphingomyelin-enriched membrane microdomains in Niemann-Pick type C disease.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Proteolytic cleavage of the hydrophobic domain in the CaVα2δ1 subunit improves assembly and activity of cardiac CaV1.2 channels.Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblastsStairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population.Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events.Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradationThe PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells.Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.
P2860
Q24294486-DFCC0C01-835D-47F5-9A10-29451BF1C319Q24297165-1DA51F3D-7F26-45CE-A14F-0BDADC77E240Q24615397-0B6ED7EC-E86C-4D92-BB57-DC7BFFDDFB79Q26786549-061D8CA5-9F21-4B5D-953B-9C67E5D07C9FQ27009477-C5FCF2E4-10D5-4435-8FF3-A469977B7B96Q27339783-53854B3E-0FAF-49D9-A586-02C8A9FAD325Q27675650-D4DF10CC-CD37-4162-AE45-F8973FFB383BQ27680601-13BB4B90-8FAD-4790-BABC-AA82488E395DQ28544991-B1148EFA-4C28-4C46-8977-4BA178DA55F9Q33532964-2BF741ED-166F-4398-B7D2-D4C1DB5F672AQ33569939-D0F12AD2-0665-4D92-908A-D73857ECD392Q33599961-A502AC13-E3F1-4B43-A53A-0853EBA41A11Q33732407-6B636D85-F372-464B-9E14-F3729CBC7338Q34169463-D44AE5B8-25ED-4CC3-A81B-60ED8C4BB36BQ34458693-192D4B80-90B3-4A0F-9953-08F7716B6BCFQ34723257-BB315773-04A3-4B81-9B92-F951526CD5B1Q35036348-7518A2D8-E03E-491E-8035-6592F2BCDCF9Q36281706-A7641CBE-D0C8-4C1E-B442-6F3C07AB4D36Q36481769-01DC17C6-DED6-48E8-9576-A6549FCFE779Q36529674-9847AE69-ED37-4CB3-A7CF-BFB3B9E5C127Q37225018-66BC8574-8196-4833-99B2-20CB62EEAD29Q37254899-E7EF3EF0-6781-4E0F-9B42-92DAC7103552Q37463260-CBCE5D7F-8849-45C0-AFA3-38B135D3FE32Q37683426-13099B19-EA8A-41F5-A5F8-DBA2136776F0Q37688760-A4198AFD-1BA6-4EDB-B65F-9781C27D4892Q37703261-162B474C-8E20-43B4-99FF-3D8994509786Q37789741-20646B0E-D0C8-4F6A-9503-E242CE0FED17Q37825903-61390C1A-0AE7-4678-B3CB-4A4F6C578743Q37967197-FAD39470-E4C6-4371-BB45-5FDB89C9EC3AQ38109960-6194D8CC-BD15-4D19-8B53-A99EDE8A0179Q38151675-F50271B9-EEA7-4C19-B89D-5FE537CF47CFQ38703819-7070DBE0-DCD5-4089-851B-D1E118BC3F88Q39051108-15804FBD-CE82-4E36-B63A-02AF3B9E0E52Q40829286-2DE268FB-FF66-4D04-8993-564117FCC499Q41020560-7D47787F-38FC-4C38-9DD2-2DE4B837CA43Q41198301-9385D995-5819-400C-B402-85D3C6504017Q42136107-72AFB3D2-B8BA-4972-B9B1-603DAF9F263BQ42367561-9F8D26C2-2E11-4E52-BFDA-ABB4B350A50DQ42505455-FC601DCC-D80A-40C1-9069-DEBB4737AD3BQ42660727-B1C2FDE2-A868-42EB-9202-519822A3A353
P2860
Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@ast
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@en
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@en-gb
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@nl
type
label
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@ast
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@en
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@en-gb
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@nl
prefLabel
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@ast
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@en
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@en-gb
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@nl
P2860
P921
P3181
P356
P1476
Annexin A2 is a C-terminal PCS ...... ty lipoprotein receptor levels
@en
P2093
Gaétan Mayer
Steve Poirier
P2860
P304
P3181
P356
10.1074/JBC.M805971200
P407
P577
2008-11-14T00:00:00Z